347 related articles for article (PubMed ID: 25140995)
1. A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves' disease.
Liu X; Qiang W; Liu X; Liu L; Liu S; Gao A; Gao S; Shi B
Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):564-7. PubMed ID: 25140995
[TBL] [Abstract][Full Text] [Related]
2. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
[TBL] [Abstract][Full Text] [Related]
3. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
4. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
Wu G; Jie Y; Situ Y
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
[TBL] [Abstract][Full Text] [Related]
5. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
[TBL] [Abstract][Full Text] [Related]
8. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
9. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
12. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
Kruljac I; Solter D; Vrkljan AM; Solter M
Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
[TBL] [Abstract][Full Text] [Related]
13. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
14. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
[TBL] [Abstract][Full Text] [Related]
15. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
17. Soluble intercellular adhesion molecule-1 and Graves' disease.
Escobar-Morreale HF; Serrano J; Sancho JM; Varela C
Thyroid; 1997 Oct; 7(5):801-3. PubMed ID: 9349588
[No Abstract] [Full Text] [Related]
18. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
Kubota S; Takata K; Arishima T; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Miyauchi A
Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]